RxDoctor Payments Data

Aizik Wolf, MD

Neurological Surgery · South Miami, FLNPI 1760443766

Payments from drug & device makers

$128,594in general payments, 2019–2025

Across 96 payments — averaging $1339.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genesys Orthopedics Systems, L.L.C.$124K
  • Insightec,inc$2K
  • Zap Surgical Systems, Inc.$1K
  • SK Life Science, Inc.$501
  • Teva Pharmaceuticals USA, Inc.$156
  • Orthofix Medical, Inc.$155
  • plus $861 from 13 others

What the payments were for

  • Royalty or licence$119,07893%
  • Consulting fees$4,5003%
  • Travel & lodging$1,0481%
  • Food & beverage$3,7823%
  • Education$540%
  • Entertainment$1320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$128,594 in reported general payments places this provider in the 80th percentile of 556 neurological surgery providers in Florida.

See all neurological surgery providers in Florida

Medicare billing

Part B allowed, 2024
$119,010
Medicare patients
175
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Carbamazepine461$21,496
XcopriCenobamate14$15,146
Carbamazepine ErCarbamazepine147$13,926
Emgality PenGalcanezumab-Gnlm12$8,430
Pregabalin287$7,181
Pentoxifylline153$4,788
Dexamethasone255$3,362
Gabapentin239$3,092
Phenytoin Sodium Extended137$2,576
Oxcarbazepine30$2,545
Lacosamide21$2,421
Duloxetine Hcl100$1,522
Baclofen44$1,066
Levetiracetam54$904
Divalproex Sodium ErDivalproex Sodium19$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$501$15,14614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 556 neurological surgery providers in Florida.

Other neurological surgery in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →